Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma

The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were searched, and the Newcastle–Ottawa Scale (NOS) was utilized to assess the study quality. Results showed that bevacizumab significantly improved overall survival (OS) (HR = 0.51; 95% CI: 0.40–0.66) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.29–0.60). The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39–60%), 17% (95% CI: 9–25%), and 31% (95% CI: 22–41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.